BaselineYear 2BaselineYear 2
DAS28(CRP)6.1±0.9†2.0±0.56.4±1.0‡2.0±0.5
DAS28(CRP)≥5.1, n (%)68 (87)†050 (91)‡0
CRP (mg/dL)3.0±2.90.4±0.24.5±4.70.5±0.2
SJC (0–66 joints)19.7±9.82.1±4.323.4±14.41.2±2.4
TJC (0–68 joints)27.2±13.21.9±4.531.0±15.21.6±3.0
HAQ-DI (range, 0–3)1.3±0.6§0.3±0.5§1.6±0.60.3±0.5
PGA (0–100 mm VAS)63.3±16.6¶5.8±7.6§66.2±18.3‡6.6±9.6
PtGA (0–100 mm VAS)62.9±24.0¶6.5±10.366.5±20.8**7.3±9.8
mTSS (range, 0–398)††12.7±13.313.4±14.018.2±25.019.4±24.7
JE (range, 0–230)††8.1±8.68.1±8.610.6±16.210.9±16.1
JSN (range, 0–168)††4.5±5.85.2±6.87.5±10.08.6±9.9
  • Data are presented as mean±SD, unless otherwise indicated.

  • *n=79 (data missing for five patients).

  • †n=78.

  • ‡n=55.

  • §n=83.

  • ¶n=81.

  • **n=54.

  • ††Baseline and year 2 (OLE year 0) mTSS, JE and JSN assessments were based on re-reads of radiographs from the year 5 campaign, which included 59 and 43 patients from the MTX non-use and MTX use populations, respectively.

  • CRP, C reactive protein; DAS28(CRP), 28-joint Disease Activity Score using C reactive protein; DMARD , (non-biologic) disease-modifying antirheumatic drug; HAQ-DI, Disability Index of the Health Assessment Questionnaire; JE, joint erosion; JSN, joint space narrowing; LDA, low disease activity; mTSS, modified total Sharp score; MTX, methotrexate; OLE, open-label extension; PGA, Physician Global Assessment; PtGA, Patient Global Assessment; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count.